At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffery Matous (Colorado Blood Cancer Institute, Denver, CO) discusses combination approaches and novel monoclonal antibodies in multiple myeloma.
The phase I MM-008 study is assessing the pharmacokinetics and safety of pomalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma and renal impairment.